ADMP inhibitors represent a specialized class of chemical compounds that target and modulate the activity of the protein ADMP (Anti-Dorsalizing Morphogenetic Protein), a member of the TGF-beta superfamily. This protein is involved in complex biochemical pathways, particularly in the regulation of developmental processes. By interacting with ADMP, these inhibitors are able to impact specific cellular signaling mechanisms, particularly those associated with morphogenetic gradients and developmental patterning. The intricate role of ADMP in modulating the balance between various growth factors like BMP (Bone Morphogenetic Protein) and other signaling molecules makes ADMP inhibitors valuable tools for investigating developmental biology and embryogenesis. They serve as molecular probes to delineate how ADMP exerts its effects on different developmental axes, such as the dorsal-ventral axis in vertebrates.
Chemically, ADMP inhibitors are diverse, often characterized by their ability to bind specific active sites or regulatory domains on the ADMP molecule. This binding disrupts the protein's interactions with other components of morphogenetic signaling pathways, thereby influencing cellular differentiation, proliferation, and apoptosis during critical stages of development. The structural diversity of ADMP inhibitors often includes small molecules or peptidomimetics that are engineered for high affinity and specificity to ADMP's active regions. Detailed biochemical studies of these inhibitors have provided insights into the conformational changes and molecular interactions necessary for ADMP's regulatory function. By inhibiting ADMP activity, these compounds offer a method to control or observe changes in the signaling dynamics that underlie the formation of complex tissue structures and patterning during development.
더보기
| 제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
|---|---|---|---|---|---|---|
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
BMP 유형 I 수용체의 저분자 억제제로, 잠재적으로 ADMP 관련 신호에 영향을 줄 수 있습니다. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
선택적 BMP 수용체 억제제는 ADMP와 관련된 신호 경로에 영향을 미칠 수 있습니다. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
BMP 유형 I 수용체를 표적으로 하여 BMP 신호를 억제하여 잠재적으로 ADMP 활성에 영향을 미칩니다. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β 수퍼패밀리 I형 액티빈 수용체 유사 키나아제를 억제하고 ADMP 관련 과정에 영향을 줄 수 있습니다. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
TGF-β 신호의 일부인 ALK4, ALK5, ALK7을 억제하여 잠재적으로 ADMP 기능에 영향을 줄 수 있습니다. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
ALK5, ALK4, ALK7을 억제하며, ADMP와 관련된 경로에 간접적으로 영향을 줄 수 있습니다. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
TGF-β 수용체 ALK5를 억제하여 잠재적으로 ADMP 관련 신호에 영향을 줄 수 있습니다. | ||||||